We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Premier Research Announces Milestone Investigational New Drug Application
News

Premier Research Announces Milestone Investigational New Drug Application

Premier Research Announces Milestone Investigational New Drug Application
News

Premier Research Announces Milestone Investigational New Drug Application

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Premier Research Announces Milestone Investigational New Drug Application"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Premier Research Group Limited has announced that it has submitted an Investigational New Drug Application which represents the 50th IND under management.

The milestone IND was submitted to the FDA’s Division of Anesthesia, Analgesia and Rheumatology Products (DAARP), and is intended to support the clinical development of a novel formulation of a non-steroidal anti-inflammatory drug for the treatment of pain.

“This submission to DAARP expands our considerable experience in CDER Divisions and supports a development program for a new drug as a 505(b)(2) NDA, a strategy used by many small to mid-sized biopharmaceutical companies”, noted James Ottinger, Vice President, Global Consulting and Compliance.

Premier Research acquired its U.S. regulatory affairs capabilities in 2006 in order to provide regulatory consulting to its U.S. and Internationally-based clients.
Advertisement